Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

PARIS--()--Regulatory News:

Cerenis Therapeutics (Paris:CEREN):

Market: Euronext Paris, Compartment C

ISIN code: FR0012616852

Date   Number of shares outstanding   Total voting rights
    Total gross (1)   Total net (2)
July 31, 2018   18,947,016   18,947,016   18,874,456

(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About Cerenis Therapeutics: www.cerenis.com
CERENIS Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular, metabolic diseases, and HDL platform technologies. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids are removed from arteries and transported to the liver for elimination from the body. In addition to advancing HDL technologies for drug delivery, CERENIS is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). Leveraging its expertise, Cerenis is developing the first platform for the targeted drug delivery by HDL dedicated to the field of oncology (immuno-oncology and chemotherapy).

CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.

Contacts

Cerenis
Tel: +33 (0)5 62 24 09 49
info@cerenis.com
or
NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
Tel: +33 (0)1 44 71 98 53
cerenis@newcap.eu

Contacts

Cerenis
Tel: +33 (0)5 62 24 09 49
info@cerenis.com
or
NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
Tel: +33 (0)1 44 71 98 53
cerenis@newcap.eu